Nodal Medical Center | NMC Research

Research site

Location

2123 West Drive Martin Luther King Jr Boulevard Suite 101, Tampa, Florida, United States of America

Site insights

Top conditions

Top treatments

Duvakitug

RO7790121

Budesonide

Allopurinol

PF-06700841

Nalbuphine

Ixekizumab

Formoterol Fumarate

Povorcitinib

Glycopyrronium

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

NMC Research

Verified by this site

Active trials

8 of 11 total trials

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA th...

Enrolling

COPD (Chronic Obstructive Pulmonary Disease)

Drug: BGF MDI 320/14.4/9.6 μg

Drug: GFF MDI 14.4/9.6 μg

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severe...

Enrolling

Ulcerative Colitis Chronic

Ulcerative Colitis

Drug: Placebo

Drug: Eltrekibart

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-1)

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) co...

Active, not recruiting

Moderately to Severely Active Ulcerative Colitis

Drug: Afimkibart

Drug: Placebo

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance...

Enrolling

Moderately to Severely Active Crohns Disease

Drug: Placebo

Drug: Afimkibart

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Enrolling

Prurigo Nodularis

Drug: Placebo

Drug: Povorcitinib

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease (STARSCAPE-1)

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate...

Enrolling

Crohn's Disease

Drug: Duvakitug

Drug: Placebo

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis (SUNSCAPE-1)

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of du...

Enrolling

Ulcerative Colitis

Drug: Placebo

Drug: Duvakitug

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO)

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the pre...

Active, not recruiting

Psoriasis

Obesity

Drug: Tirzepatide

Drug: Ixekizumab